Application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by hyperuricemia

A hyperuricemia, luteolin technology, applied in the field of medicine, to reduce uric acid reabsorption, easy to take, reduce kidney swelling

Inactive Publication Date: 2020-07-10
HUBEI UNIVERSITY OF MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether luteolin can reduce uric acid and improve renal injury by regulating uric acid transporter has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by hyperuricemia
  • Application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by hyperuricemia
  • Application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by hyperuricemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Animal modeling and group administration, the specific steps are as follows:

[0042] 1. Experimental animals

[0043] Seventy SPF-grade ICR male mice were randomly divided into 7 groups, 10 in each group, weighing 22±2g, purchased from the Experimental Animal Center of Hubei University of Medicine, certificate number: NO.42000900000308. The mice were housed in separate cages, with free access to water and food, at room temperature (25±2)°C, and relative humidity of 50%-70%.

[0044] 2. Drugs and reagents

[0045] Oxonic acid potassium salt (Sigma); Hypoxanthine (Sigma); Benzbromarone (Yichang Changjiang Pharmaceutical Co., Ltd.); Febuxostat (Huazhong Haiwei); Luteolin (Baoji Chenguang).

[0046] 3. Experimental method

[0047] 3.1 Establishment, administration and materials collection of hyperuricemia animal model

[0048] 70 SPF grade ICR male mice were divided into 7 groups, 10 in each group, respectively solvent control group, model group, positive drug control ...

Embodiment 2

[0056] Serum uric acid, creatinine, blood urea nitrogen level detection is carried out to the serum that embodiment 1 gets

[0057] 1. Drugs and reagents

[0058] Uric acid, creatinine, and urea nitrogen detection kits were purchased from Nanjing Jiancheng Institute of Bioengineering, and the article numbers were C012-2, C011-1, and C013-2, respectively.

[0059] 2. Experimental method

[0060] The serum obtained by the above centrifugation was placed on ice, and the levels of serum uric acid, serum creatinine, and serum urea nitrogen in mice were detected according to the instructions of the Nanjing Jiancheng kit.

[0061] 3. Experimental results

[0062] 3.1 Luteolin can significantly reduce the serum uric acid level in HUA mice

[0063] image 3 It is the effect of luteolin on the blood uric acid of hyperuricemia model mice. It can be seen from the figure that compared with the solvent control group, the serum uric acid level of the model group mice has significant stat...

Embodiment 3

[0067] Embodiment 3 carries out histopathological examination to the kidney and liver that embodiment 1 gets

[0068] 1. Drugs and reagents

[0069] Hematoxylin-eosin (HE) staining kit was purchased from Beyontine Biotechnology Co., Ltd., item number is C0105.

[0070] 2. Experimental method

[0071] The kidney and liver tissues of the mice were fixed in 4% paraformaldehyde fixative for 24 hours, then dehydrated, transparentized, soaked in wax and embedded in paraffin in a tissue embedding machine. Use a rotary microtome to slice serially (3-4μm thickness), HE staining, after dewaxing, washing, differentiation, bluing, eosin staining, dehydration, transparent and mounting, observe the disease of kidney and liver tissue under a microscope Physical changes.

[0072] 3. Experimental results

[0073] 3.1 Luteolin can reverse kidney damage caused by high uric acid

[0074] Such as Figure 6 As shown, the HE staining results of the mouse kidney showed that the model control gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of luteolin and derivatives thereof in medicines for preventing and treating hyperuricemia and improving kidney injury caused by the hyperuricemia. The invention studies and determines that the luteolin and derivatives thereof can reduce serum uric acid level by inhibiting the activity of xanthine oxidase, and studies and determines for the first time that the luteolin and derivatives thereof can achieve the effects of preventing and treating the hyperuricemia and improving kidney injury caused by the hyperuricemia by adjusting the expression level of uric acid transporter. The invention provides a new application of the luteolin and derivatives thereof in preventing and treating the hyperuricemia and improving kidney injury caused by the hyperuricemia,and provides a new drug choice for preventing and treating the hyperuricemia and improving kidney injury caused by the hyperuricemia. The component has no obvious toxic or side effect, and is definitein curative effect, safe, controllable, cheap and easy to obtain.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of luteolin and its derivatives in preventing and treating hyperuricemia and improving kidney damage caused by hyperuricemia. Background technique [0002] According to reports, there are about 120 million patients with hyperuricemia (Hyperuricemia, HUA) in my country (accounting for about 10% of the total population), of which 19.4% are males and 7.9% are females. The disease has become the "fourth high" after the "three highs" of hypertension, hyperglycemia, and hyperlipidemia. Uric acid is the end product of purine metabolism in the body, and it is also the material basis of hyperuricemia and gout attacks. There are two main ways for the production of uric acid in the human body: one is through the catabolism of foods rich in purines (exogenous), accounting for 20% of the total amount of uric acid in the human body; the other is through the decomp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P19/06A61P13/12
CPCA61K31/352A61P19/06A61P13/12
Inventor 李飞余惠凡张朔桂利利吴正坤张艳
Owner HUBEI UNIVERSITY OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap